Price T Rowe Associates Inc Immuno Gen, Inc. Transaction History

Price T Rowe Associates Inc

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $35.1 Million - $84.4 Million	-2,818,157 Reduced 72.14%	1,088,213 $32.3 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $22.3 Million - $31.5 Million	1,584,109 Added 68.21%	3,906,370 $62 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $8.28 Million - $44.3 Million	2,208,333 Added 1938.36%	2,322,261 $43.8 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $32,582 - $43,679	8,878 Added 8.45%	113,928 $438,000
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $19,232 - $26,672	4,227 Added 4.19%	105,050 $521,000
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $234,796 - $339,092	52,410 Added 108.26%	100,823 $482,000
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $4,473 - $8,179	1,420 Added 3.02%	48,413 $218,000
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $46,519 - $81,681	10,920 Added 30.27%	46,993 $224,000
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $245,171 - $387,112	-51,615 Reduced 58.86%	36,073 $268,000
Q3 2021 Nov 15, 2021	BUY	$5.02 - $6.59 $3,945 - $5,179	786 Added 0.9%	87,688 $497,000
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $18,041 - $26,797	3,116 Added 3.72%	86,902 $573,000
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $59,761 - $96,812	9,194 Added 12.33%	83,786 $679,000
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $275,990 - $571,374	74,592 New	74,592 $481,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.